title: [Anti-ribosomal antibodies in systemic lupus erythematosus].
abstract: OBJECTIVE
  To compare indirect immunofluorescence (IIF) with immunoblotting (IB) in the detection of antiribosomal antibodies (anti-P Ab) in patients with systemic lupus erythematosus (SLE) and to investigate the possible association between anti-P Ab with serological and clinical findings in SLE, particularly with neurological manifestations.
  
  
  METHODS
  Serum specimens from 44 SLE patients and 10 healthy subjects were investigated for anti-P Ab using IB and IIF in rat triple substrate and HEp-2 cells. In SLE patients measurements were made of antinuclear Ab, anti-DNA ds Ab, anti-Sm Ab, anti-U1RNP Ab, anti-Ro Ab, and anti-La Ab. Clinical manifestations of SLE were collected retrospectively when the serological investigation was made.
  
  
  RESULTS
  Of the 44 serum specimens tested, 9 showed a ribosomal pattern with triple rat substrate; 8 of them were IB positive (sensitivity 88%; specificity 97%); 12 serum specimens showed a ribosomal pattern with HEp-2 cells by the IIF technique, 9 were positive by IB (sensitivity 100%; specificity 91%). All ten healthy subjects were negative both with IIF and with IB. The nine patients with anti-P Ab in IB (20.45%) had anti-Ro Ab (55% vs. 37%), Anti-Sm Ab (33% vs. 22%, and U1RNP Ab (33% vs. 20%) more frequently than the 35 negative cases. Central nervous system disease (33 vs. 14%), and particularly seizures (33% vs. 5%) and psychosis (22% vs. 8%) were more common in cases with anti-P Ab, but as with serological associations, none of them reached a statistical signification.
  
  
  CONCLUSIONS
  IIF with both rat triple substrate and HEp-2 cells is useful for the presumptive diagnosis of anti-P Ab in patients diagnosed with SLE. No significant serological or clinical association was found in patients with anti-P Ab, although neurological disease was more common in these cases.
authors.affiliation: Servicio de Reumatología, Hospital Ramón y Cajal, Madrid.
authors.forename: J M
authors.initials: JM
authors.lastname: Corres González
authors.forename: C
authors.initials: C
authors.lastname: Rodríguez Hernández
authors.forename: A C
authors.initials: AC
authors.lastname: Zea Mendoza
authors.forename: J
authors.initials: J
authors.lastname: Sequí Navarro
authors.forename: I
authors.initials: I
authors.lastname: Sanchidrián Fernández
mesh_terms: D001323:Autoantibodies / Q000032:analysis*; D002493:Central Nervous System Diseases / Q000150:complications / Q000276:immunology; D005455:Fluorescent Antibody Technique; D006801:Humans; D015151:Immunoblotting; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000276:immunology*; D015800:Protozoan Proteins; D012269:Ribosomal Proteins / Q000276:immunology*; D012680:Sensitivity and Specificity
chemical_list: D001323:Autoantibodies; C064601:L12E protein, Trypanosoma cruzi; D015800:Protozoan Proteins; D012269:Ribosomal Proteins
vernacular_title: Anticuerpos antirribosomales en le lupus eritematoso sistémico.